Baidu
map

J Am Acad Dermatol:相比非银屑病患者,银屑病患者严重感染的患病率和发病率均明显增高

2016-06-20 Mechront 译 MedSci原创

最近发表的研究结果显示,美国的住院病人中,银屑病患者与非银屑病患者相比,严重感染的患病率和发病率均明显增高。 西北大学费因伯格医学院皮肤科的Jonathan I. Silverberg博士和同事对2002-2012年的全国住院样本进行了一项横断面研究,从数据库中确定患者出院时的主要和/或次要诊断,以及严重感染情况。研究者试图确定住院的银屑病患者严重感染的发病率和预测因子,并量化护理费用、住

最近发表的研究结果显示,美国的住院病人中,银屑病患者与非银屑病患者相比,严重感染的患病率和发病率均明显增高。

西北大学费因伯格医学院皮肤科的Jonathan I. Silverberg博士和同事对2002-2012年的全国住院样本进行了一项横断面研究,从数据库中确定患者出院时的主要和/或次要诊断,以及严重感染情况。研究者试图确定住院的银屑病患者严重感染的发病率和预测因子,并量化护理费用、住院时间和死亡率。

数据显示,银屑病患者年龄高于非银屑病患者(59.9岁和47.9岁),患银屑病的女性较少(47.5%比58.6%),银屑病和非银屑病住院患者的严重感染率为28.2%和21%。

多元回归Logistic模型分析显示,与银屑病相关严重感染有:MRSA (OR = 1.76; 95% CI, 1.52-2.03);蜂窝组织炎(OR = 3.21; 95% CI, 3.12-3.3);单纯疱疹病毒感染(OR = 2.21; 95% CI, 1.7-2.89);感染性关节炎(OR = 1.82; 95% CI, 1.58-2.09);骨髓炎(OR = 1.31; 95% CI, 1.18-1.46);脑膜炎(OR = 1.31; 95% CI, 1.16-1.47);脑炎(OR = 1.22; 95% CI, 1.02-1.47)和结核(OR = 1.34; 95% CI, 1.2-1.49)。

研究人员写道:银屑病患者的严重感染率增加了所有的时间间隔分析(P = .01),并且显著高于非银屑病患者(P < .0001)。

银屑病患者中严重感染者住院时间更长(6.6天 vs.4.6天)、花费更多(13291美元 vs.11003美元)(P < .0001)。

研究结果表明,银屑病患者严重感染的患病率和发病率均明显增高。此外,银屑病患者其他感染的几率较高,如结核、脑膜炎和真菌感染,不过还需要进一步的研究来证实这些发现。

原始出处:

Hsu DY, et al. Serious infections in hospitalized patients with psoriasis in the United States.J Am Acad Dermatol. 2016;doi:10.1016/j.jaad.2016.04.005.

Serious infection prevalence higher for inpatients with psoriasis vs. those without.Healio.June 17, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1651822, encodeId=a3a31651822fb, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Apr 30 03:37:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823281, encodeId=d56d1823281fe, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 16:37:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250432, encodeId=a0c9125043241, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561578, encodeId=11eb15615e876, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567587, encodeId=26a3156e5873e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594222, encodeId=386915942225d, content=<a href='/topic/show?id=c5c9211855f' target=_blank style='color:#2F92EE;'>#严重感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21185, encryptionId=c5c9211855f, topicName=严重感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90663, encodeId=a0b890663f9, content=因果关系呢,互为因果么, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Jun 20 18:08:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90631, encodeId=491b90631a9, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:21:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90630, encodeId=dfbb9063059, content=很不错啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:20:00 CST 2016, time=2016-06-20, status=1, ipAttribution=)]
    2017-04-30 lishizhe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1651822, encodeId=a3a31651822fb, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Apr 30 03:37:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823281, encodeId=d56d1823281fe, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 16:37:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250432, encodeId=a0c9125043241, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561578, encodeId=11eb15615e876, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567587, encodeId=26a3156e5873e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594222, encodeId=386915942225d, content=<a href='/topic/show?id=c5c9211855f' target=_blank style='color:#2F92EE;'>#严重感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21185, encryptionId=c5c9211855f, topicName=严重感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90663, encodeId=a0b890663f9, content=因果关系呢,互为因果么, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Jun 20 18:08:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90631, encodeId=491b90631a9, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:21:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90630, encodeId=dfbb9063059, content=很不错啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:20:00 CST 2016, time=2016-06-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1651822, encodeId=a3a31651822fb, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Apr 30 03:37:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823281, encodeId=d56d1823281fe, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 16:37:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250432, encodeId=a0c9125043241, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561578, encodeId=11eb15615e876, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567587, encodeId=26a3156e5873e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594222, encodeId=386915942225d, content=<a href='/topic/show?id=c5c9211855f' target=_blank style='color:#2F92EE;'>#严重感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21185, encryptionId=c5c9211855f, topicName=严重感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90663, encodeId=a0b890663f9, content=因果关系呢,互为因果么, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Jun 20 18:08:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90631, encodeId=491b90631a9, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:21:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90630, encodeId=dfbb9063059, content=很不错啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:20:00 CST 2016, time=2016-06-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1651822, encodeId=a3a31651822fb, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Apr 30 03:37:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823281, encodeId=d56d1823281fe, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 16:37:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250432, encodeId=a0c9125043241, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561578, encodeId=11eb15615e876, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567587, encodeId=26a3156e5873e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594222, encodeId=386915942225d, content=<a href='/topic/show?id=c5c9211855f' target=_blank style='color:#2F92EE;'>#严重感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21185, encryptionId=c5c9211855f, topicName=严重感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90663, encodeId=a0b890663f9, content=因果关系呢,互为因果么, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Jun 20 18:08:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90631, encodeId=491b90631a9, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:21:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90630, encodeId=dfbb9063059, content=很不错啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:20:00 CST 2016, time=2016-06-20, status=1, ipAttribution=)]
    2016-06-22 liuxiaona
  5. [GetPortalCommentsPageByObjectIdResponse(id=1651822, encodeId=a3a31651822fb, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Apr 30 03:37:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823281, encodeId=d56d1823281fe, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 16:37:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250432, encodeId=a0c9125043241, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561578, encodeId=11eb15615e876, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567587, encodeId=26a3156e5873e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594222, encodeId=386915942225d, content=<a href='/topic/show?id=c5c9211855f' target=_blank style='color:#2F92EE;'>#严重感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21185, encryptionId=c5c9211855f, topicName=严重感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90663, encodeId=a0b890663f9, content=因果关系呢,互为因果么, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Jun 20 18:08:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90631, encodeId=491b90631a9, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:21:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90630, encodeId=dfbb9063059, content=很不错啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:20:00 CST 2016, time=2016-06-20, status=1, ipAttribution=)]
    2016-06-22 liuxiaona
  6. [GetPortalCommentsPageByObjectIdResponse(id=1651822, encodeId=a3a31651822fb, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Apr 30 03:37:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823281, encodeId=d56d1823281fe, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 16:37:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250432, encodeId=a0c9125043241, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561578, encodeId=11eb15615e876, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567587, encodeId=26a3156e5873e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594222, encodeId=386915942225d, content=<a href='/topic/show?id=c5c9211855f' target=_blank style='color:#2F92EE;'>#严重感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21185, encryptionId=c5c9211855f, topicName=严重感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90663, encodeId=a0b890663f9, content=因果关系呢,互为因果么, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Jun 20 18:08:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90631, encodeId=491b90631a9, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:21:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90630, encodeId=dfbb9063059, content=很不错啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:20:00 CST 2016, time=2016-06-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1651822, encodeId=a3a31651822fb, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Apr 30 03:37:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823281, encodeId=d56d1823281fe, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 16:37:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250432, encodeId=a0c9125043241, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561578, encodeId=11eb15615e876, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567587, encodeId=26a3156e5873e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594222, encodeId=386915942225d, content=<a href='/topic/show?id=c5c9211855f' target=_blank style='color:#2F92EE;'>#严重感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21185, encryptionId=c5c9211855f, topicName=严重感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90663, encodeId=a0b890663f9, content=因果关系呢,互为因果么, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Jun 20 18:08:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90631, encodeId=491b90631a9, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:21:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90630, encodeId=dfbb9063059, content=很不错啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:20:00 CST 2016, time=2016-06-20, status=1, ipAttribution=)]
    2016-06-20 1df01bccm39(暂无匿称)

    因果关系呢,互为因果么

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1651822, encodeId=a3a31651822fb, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Apr 30 03:37:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823281, encodeId=d56d1823281fe, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 16:37:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250432, encodeId=a0c9125043241, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561578, encodeId=11eb15615e876, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567587, encodeId=26a3156e5873e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594222, encodeId=386915942225d, content=<a href='/topic/show?id=c5c9211855f' target=_blank style='color:#2F92EE;'>#严重感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21185, encryptionId=c5c9211855f, topicName=严重感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90663, encodeId=a0b890663f9, content=因果关系呢,互为因果么, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Jun 20 18:08:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90631, encodeId=491b90631a9, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:21:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90630, encodeId=dfbb9063059, content=很不错啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:20:00 CST 2016, time=2016-06-20, status=1, ipAttribution=)]
    2016-06-20 milkshark

    努力学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1651822, encodeId=a3a31651822fb, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Apr 30 03:37:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823281, encodeId=d56d1823281fe, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 16:37:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250432, encodeId=a0c9125043241, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561578, encodeId=11eb15615e876, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567587, encodeId=26a3156e5873e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594222, encodeId=386915942225d, content=<a href='/topic/show?id=c5c9211855f' target=_blank style='color:#2F92EE;'>#严重感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21185, encryptionId=c5c9211855f, topicName=严重感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 22 02:37:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90663, encodeId=a0b890663f9, content=因果关系呢,互为因果么, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Mon Jun 20 18:08:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90631, encodeId=491b90631a9, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:21:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90630, encodeId=dfbb9063059, content=很不错啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 20 12:20:00 CST 2016, time=2016-06-20, status=1, ipAttribution=)]
    2016-06-20 milkshark

    很不错啊

    0

相关资讯

加拿大皮肤-风湿病学倡议小组的专家建议

近几年,随着对炎性疾病发病机制及临床特征的深入了解,人们越来越关注炎性疾病伴随疾病的治疗及其在预后中的作用,多学科合作共同诊治炎性疾病多系统并发症已成为当今热点:2015年7月加拿大皮肤一风湿病学倡议小组在J Rheumatol上发表了一篇关于RA、银屑病(psoriasis)和PsA伴随疾病的管理建议。 该项工作共纳入1960-2012年Medline、EMbase、Cochrane图书馆三大

世界银屑病日:关注银屑病遗传易感性

银屑病是一种具有遗传倾向的慢性、复发性、炎症性疾病,可累及多个系统。从患者角度而言,银屑病严重影响形象及生活质量,被比作无法根治的慢性癌症。目前全球银屑病患者已达到了1.25亿之多,而我国银屑病患者数量约800万。 2004年7月,来自世界各地的银屑病患者和非银屑病患者代表组成了银屑病指导委员会。同时,由国际银屑病协会(IFPA)提出,会议一致通过将今后每年10月29日定为“世界银屑病日”。目前

FDA批准银屑病治疗药Taltz

美国FDA批准Eli Lilly的Taltz (ixekizumab) 来治疗中度至重度斑块状银屑病。银屑病是一种皮肤发红和剥落的皮肤状况。银屑病是一种自身免疫性的紊乱,通常发生在家族史患者,最常在 15 至 35 岁开始。银屑病最常见的形式是斑块状银屑病,病人形成厚厚的红色皮肤片状,银白色鳞片状结构。 FDA 的药物评价和研究中心办公室主任医学博士Julie Bei

诺华Cosentyx单抗治疗银屑病患者52周时的疗效优于Stelara,表现为持久性皮损消退(PASI 90)

美国皮肤病学会(AAD)2016年的新数据表明在治疗52周1 时,Cosentyx®保持皮损消退(PASI 90至PASI 100)的疗效显著优于Stelara。用Cosentyx治疗, 10名中重度银屑病患者中,接近8名患者达到并保持皮损消退(PASI 90至PASI 100)。1 在欧洲Cosentyx被确定为治疗银屑病的一线系统用药,近期又在美国和欧洲被批准用于治疗银屑病关节炎和强

Ann Rheum Dis:银屑病,尤忌吸烟(DANBIO注册研究)

目的:银屑病在常规护理中使用第一肿瘤坏死因子抑制剂(TNFi),本次旨在研究在这种治疗方式下吸烟对银屑病的活动性、依从性和治疗反应性的影响。方法:观察性队列研究,数据由丹麦全国性DANBIO登记处提供,通过吸烟状态分组(目前吸烟、曾吸烟、从不吸烟),采用K-M曲线、logistics和cox回归曲线分析治疗的依从性、反应性(ACR20/50/70、SULAR良好反应性)。另外根据性别和TNFi亚型

BMJ:银屑病可增加腹主动脉瘤的发生风险

来自丹麦Gentofte医院的一项新的研究发现,银屑病可增加腹主动脉瘤的发生风险,且这种风险与银屑病的严重程度呈正相关,该研究结果已在线发表于 Arteriosclerosis, Thrombosis, and Vascular Biology。

Baidu
map
Baidu
map
Baidu
map